Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Neil

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Clinical Genitourinary Cancer|February 4, 2022
Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma PatientsMyuran Thana, Naveen S Basappa, Sunita Ghosh, et al.
Forensic Science International|November 8, 2016
A comment on the PCAST report: Skip the "match"/"non-match" stageGeoffrey Stewart Morrison, David H Kaye, David J Balding, et al.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Clinical Genitourinary Cancer|February 4, 2022
Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma PatientsMyuran Thana, Naveen S Basappa, Sunita Ghosh, et al.
Forensic Science International|November 8, 2016
A comment on the PCAST report: Skip the "match"/"non-match" stageGeoffrey Stewart Morrison, David H Kaye, David J Balding, et al.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
Pageof 3